Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.

Colonna, P; Jaı̈s, Jean-Philippe; Desablens, B; Harousseau, J L; Brière, J; Boasson, M; Lemevel, A; Casassus, Philippe; Prise, P. Y. Le; Guilhot, Joëlle; Ghandour, C; Lejeune, Françoise; Andrieu, Jean‐Marie

doi:10.1200/jco.1996.14.6.1928

Cited by 43 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients were classified in CS IA to IVB according to the Ann Arbor criteria. [6][7][8][9][10] Of these 955 patients, 500 had CS IA and IIA.…”

Section: Clinical Stagingmentioning

confidence: 99%

“…[6][7][8] Of these, the 34 patients with peripheral CS IA (ie, without supraclavicular or mediastinal disease) received only one ABVD cycle (doxorubicin 25 mg/m 2 , bleomycin 10 mg/m 2 , vinblastine 6 mg/m 2 , and dacarbazine 375 mg/m 2 plus methylprednisolone 120 mg/m 2 administered intravenously on days 1 and 15). The 167 other patients received 3 ABVD cycles.…”

Section: Chemotherapies Given To Cs Ia and Iiamentioning

confidence: 99%

“…In these trials, patients were treated by a brief chemotherapy (CT) followed by an extended-field radiotherapy (RT) regimen. [6][7][8][9][10] Among the 955 patients with HL at clinical stage (CS) IA to IVB recruited in these trials, 74 patients were initially classified as having lymphocyte predominance according to the Rye classification. The pathologic material (lymph node biopsies) of these 74 patients was centrally reviewed and LPHL (according to the REAL/WHO definitions) was found in 44 patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

Feugier

2004

Blood

View full text Add to dashboard Cite

“…Patients were classified in CS IA to IVB according to the Ann Arbor criteria. [6][7][8][9][10] Of these 955 patients, 500 had CS IA and IIA.…”

Section: Clinical Stagingmentioning

confidence: 99%

Section: Chemotherapies Given To Cs Ia and Iiamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

Feugier

2004

Blood

View full text Add to dashboard Cite

“…34,35 However, response as measured by computed tomography scan might occur with some delay in advanced HL. This is likely due to the fibrotic tissue infiltrating lymph nodes in this disease, which often results in residual masses remaining several months after therapy.…”

Section: What Do We Know About Positron Emission Tomography?mentioning

confidence: 99%

The Past: What We Have Learned in the Last Decade

Borchmann

Engert

2010

Hematology

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) has become a curable malignancy for most patients during the last decades. However, many controversies still exist on the optimal strategy of how to cure our patients. The key question is how to balance the risks and toxicities of chemotherapy and radiotherapy against the need for a definite treatment for early or advanced-stage HL patients. However, although many studies have been conducted and reported during the past decade, interpretation of their results and treatment recommendations might vary significantly in different countries. For example, early-stage HL might be divided into two different subgroups: early favorable and early unfavorable or not. Treatment of early-stage HL might include radiotherapy ("combined modality") or not. Depending on the extent of radiotherapy, the schedule and number of chemotherapy cycles are also questioned. For advanced-stage HL, the situation is not much different. Compared with ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine), the more aggressive escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) is highly effective, but also raises concern due to excessive toxicity. Thus, there is a controversy about the standard of care for advanced HL patients. Because no mature results comparing these approaches with each other are currently available, it remains our duty to share the preliminary information with our patients and to figure out the most appropriate individual treatment strategy. Of course, the discussion of these issues is influenced by experiences and preferences. In contrast, in this article, we will try to focus on the available scientific evidence regarding the first-line treatment of HL. Of course, focusing on the last decade necessarily exclude the most recent results from ongoing studies. Thus, even though this article comprises treatment recommendations for HL patients, the best treatment certainly still is within properly designed prospective clinical trials.

show abstract

“…Patients in the H81 trial were initially treated with three cycles of ABVD and then received a high-dose extended field irradiation. 10,11 Patients in the H90 trial were initially treated with three or four cycles (according to a randomization) of a seven-drug combination chemotherapy and then received a high-dose extended field irradiation. 12 Patients were identified through a search of the GOELAMS group's computerized Hodgkin's disease data base.…”

Section: Combined-modality Treatmentmentioning

confidence: 99%

Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy

Vigouroux¹,

Milpied²,

Andrieu

et al. 2002

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

Summary:This retrospective study compares high-dose therapy (HDT) with autologous stem cell transplantation and combined-modality treatment (CT) as a first-line therapy for Hodgkin's disease (HD) for patients with both a clinical stage (CS) IV and/or a mediastinal mass у0.45 of the thoracic diameter (MM у0.45) at diagnosis, and an incomplete response after the first-line chemotherapy. Data on 42 grafted patients (GP) in Nantes Hospital, France and on 108 combined-modality treated patients (CTP) from two protocols of the GOELAMS group, France (POF 81 and H90) was analyzed. Both groups were comparable except for pulmonary disease in excess in the grafted group (P ‫؍‬ 0.01). Among GP, 95% were in complete response at the end of first-line treatment and 77% among CTP. Median follow-up was 53 months (range, 7 to 128 months) for GP and 88 months (range, 25 to 181 months) for CTP. The 5-year freedom from progression (FFP) and event-free survival (EFS) rates were better for GP (87% vs 55% for FFP: P ‫؍‬ 0.0004 and 81% vs 51% for EFS: P ‫؍‬ 0.0004) whereas the overall survival (OS) rates did not differ significantly (85% for GP vs 71% for CTP: P ‫؍‬ 0.06). Similar results were obtained for the groups with a response у50% after initial chemotherapy: 91% vs 65% for FFP, P ‫؍‬ 0.01; 87% vs 61% for EFS, P ‫؍‬ 0.02; and 92% vs 77% for OS, P ‫؍‬ 0.2; and for the groups with a response Ͻ50%: 80% vs 22% for FFP, P ‫؍‬ 0.0003; 72% vs 13% for EFS, P ‫؍‬ 0.0001; and 76% vs 46% for OS, P ‫؍‬ 0.04. This study shows a better control of the disease with HDT.

show abstract

Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.

Abstract: These results demonstrate the independent impact on HD prognosis of tumor burden and post-CT status.

Cited by 43 publications

References 20 publications

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation

The Past: What We Have Learned in the Last Decade

Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy

Contact Info

Product

Resources

About